Trending...
- New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
- Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
- Thou Shalt not Commit Adultery Lifetime Movie Discussion
PHILADELPHIA, Dec. 4, 2024 ~ Franklin Biolabs, a newly established contract research organization (CRO) focused on genetic medicines, has announced the appointment of Vatsala Naageshwaran, PhD, as its Chief Executive Officer. The company was founded by renowned gene therapy pioneer, James Wilson, MD, PhD.
Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.
"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."
More on The PennZone
Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.
Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.
"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."
More on The PennZone
Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.
Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.
With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.
"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."
More on The PennZone
- Community, Conservation & Waterwise Inspiration Bloom on June 6
- Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
- Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
- CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
- Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup
Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.
Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.
"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."
More on The PennZone
- Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
- Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health
- Blueshirt Media Launches HIPAA-Compliant AI Call Answering for Addiction Treatment Centers
- AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
- UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.
Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.
With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
Filed Under: Business
0 Comments
Latest on The PennZone
- Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform
- New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
- The Calida Group Announces Sale of Ely at Fort Apache for $57.5 Million
- Tina Hasselbusch, co-founder and CEO of Turnstone Creative, Receives Circle of Excellence from Lehigh Valley Business
- Summer Festivals in Gunma Prefecture: Song, Dance, and Vibrant Color – Get There Via Tobu Railway!
- Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
- AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure
- Early Bird Registration Open for FLYING HY, the Top Hydrogen and Battery Electric Aviation Event
- Eichelberger Performing Arts Center Welcomes New Executive Director
- Century Fasteners Corp. Hires Tony Marano as Director of Human Resources
- Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
- New Wisconsin Report Shows Most Plane Crashes Happen Outside Major Hubs
- Thou Shalt not Commit Adultery Lifetime Movie Discussion
- Book Florida Keys Accommodations Early with KeysCaribbean and Save 15 Percent
- Color Card Administrator Highlights Growing Enterprise Demand for Workflow Orchestration in Enterprise Business Card Governance
- Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
- Curious About Mensa? DFW Event Offers a 1-Day Immersion
- Morphy's will breeze into summer with a June 10-11 Fine & Decorative Arts auction featuring nearly 1,200 high-quality lots
- L-Tron to Exhibit at American Association for Motor Vehicle Administrators Region 1 Conference
- Buzzblender Announces Launch of Simple Hotel Mode for Android and Upcoming Video Wall Support for Samsung Professional Displays